Skip to main content
Signal8

Yarrow Bioscience, Inc. Form SCHEDULE 13D/A — Nov 20, 2026

Form SCHEDULE 13D/AFiled Nov 20, 2026, 9:41 PM ET0001193125-26-470747Original filing

AI Biotechnology LLC, Access Industries Holdings LLC, Access Industries Management LLC and Len Blavatnik filed Amendment No. 2 to their Schedule 13D on Yarrow Bioscience, Inc., reporting beneficial ownership of 178,179 shares of common stock, or approximately 1.16% of the class. The amendment states that on November 13, 2026, the Reporting Persons ceased to be beneficial owners of more than five percent of Yarrow Bioscience's outstanding common stock, implying prior sales or disposition of their position. The holdings consist of 22,331 shares plus warrants to purchase 155,848 shares, held directly by AI Biotechnology, with each entity and Mr.

Key figures

Shares Outstanding
0
Warrant shares
155848
Amendment number
2
Date ceased 5pct
2026-11-13
Percent of class
1.16%
Shares owned directly
22331
Shares beneficially owned
178179

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    Yarrow Bioscience, Inc. Form SCHEDULE 13D/A — Nov 20, 2026: AI Analysis | Signal8